USPTO serial 87521290
NHI
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- GULIANO, ROBERT N
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with NHI?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Saint-Maur-des fosses, FR
Saint-Maur-des fosses, FR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jason J. Mazur
JASON J. MAZUR ARENT FOX LLP1717 K STREET, NWWASHINGTON, DC 20006-5344UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical products namely, acne medication, allergy medication, antacids, anthelmintics, antiarrhythmics, antibiotic creams and ointments, antibiotics, anticoagulants, anticonvulsants, antidepressants, antiemetics, antiflatulants, antihistamines, antihypertensives anti-infectives, anti-inflammatories, antiparasites, antivirals, burn relief medication, calcium channel blockers, central nervous system depressants, central nervous system stimulants, cough treatment medication, diarrhea medication, fungal medications, gastro-intestinal pharmaceutical preparations, glaucoma agents, hydrocortisone, hypnotic agents, sedatives, pain relief medication, and topical and injectable pharmaceutical products for dental, endodontic and periodontal disorders; anti-diabetic pharmaceuticals; anti-epileptic pharmaceutical preparations; bismuth preparations for pharmaceutical use; bromine for pharmaceutical purposes; cardiovascular pharmaceutical preparations; frostbite salve for pharmaceutical purposes; guaiacol for pharmaceutical purposes; intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; injectable pharmaceutical contraceptives; pharmaceutical anti-allergic preparations and substances; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of bone fractures; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for reducing cholesterol; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the relief of pain; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of carpal tunnel syndrome; pharmaceutical preparations for the treatment of chronic pain; pharmaceutical preparations for the treatment of cranial or facial nerve disorders; pharmaceutical preparations for the treatment of degenerative nerve diseases and disorders, namely, Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis; pharmaceutical preparations for the treatment of dental and oral diseases; pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely, growth and thyroid disorders; pharmaceutical preparations for the treatment of diseases, disorders and infections of the spinal cord systems and related cartilage and tissue; pharmaceutical preparations for the treatment of drug and alcohol abuse; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, namely, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of glaucoma; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of infectious diseases, namely, respiratory infections, eye infections; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely, diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of metabolic disorders, namely, diabetes, bulimia nervosa, anorexia, obesity and hypothyroidism; pharmaceutical preparations for the treatment of migraine; pharmaceutical preparations for the treatment of motion sickness; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of myalgia and neuralgia; pharmaceutical preparations for the treatment of neurological diseases, namely, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis, myasthenia gravis, Huntington's disease; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment of physical and psychological addictions, namely, gambling addiction, eating disorders and addictions, nicotine addiction, Internet addiction, drug addiction; pharmaceutical preparations for the treatment of psychiatric and other brain diseases and disorders, namely, anxiety, mood disorders, schizophrenia, cognitive and bipolar disorders, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple sclerosis; pharmaceutical preparations for the treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia; pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; pharmaceutical preparations for the treatment of skin irritations, namely, bee stings, sunburn, rashes, sores, corns, calluses, and acne; pharmaceutical preparations for the treatment of smoking cessation; pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases; pharmaceutical preparations for the treatment of the central nervous system, namely, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease; pharmaceutical preparations for the treatment of the diseases, disorders and infections of the central nervous system, namely, brain, movement, ocular motility and spinal cord diseases; pharmaceutical preparations for the treatment of the musculoskeletal system, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for the treatment of varicose veins; pharmaceutical preparations for the treatment of vascular diseases; pharmaceutical preparations for the treatment of viral diseases, namely, herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS); pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treating asthma; pharmaceutical preparations for treating dandruff; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases; pharmaceutical preparations for use in discouraging the smoking habit; pharmaceutical preparations for use in gastroenterology; pharmaceutical preparations for use in ocular disorders; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for wounds; pharmaceutical products and preparations against dry skin caused by pregnancy; pharmaceutical products and preparations for hydrating the skin during pregnancy; pharmaceutical products for ophthalmological use; pharmaceutical products for the treatment of cancer; pharmaceutical products for treating respiratory diseases; pharmaceutical solutions used in dialysis; radioactive pharmaceutical preparations for in vivo diagnostic or therapeutic use; sunburn preparations for pharmaceutical purposes; synthetic peptides for pharmaceutical purposes for the prevention and treatment of inflammatory disorders and diseases, gastroenterological disorders and diseases, nervous system disorders and diseases, immune system disorders and diseases, cardiovascular disorders and diseases, metabolic disorders and diseases, respiratory disorders and diseases, musculo-skeletal disorders and diseases, genitourinary disorders and diseases, endocrine disorders and diseases, acne, allergies, heartburn, indigestion, upset stomach, parasitic disorders and diseases, abnormal heart rhythms, bacterial infections, coagulation of blood, epileptic seizures, epilepsy, depression, vomiting, nausea, intestinal gas, allergies, hypertension, infections, inflammation, viruses, burns, low blood pressure, high blood pressure, anxiety, stress, panic attacks, attention deficit hyperactivity disorder, narcolepsy, coughing, diarrhea, fungal infections, gastrointestinal disorders and diseases, glaucoma, skin conditions, insomnia, irritability, excitement, pain, dental disorders and diseases, oral disorders and diseases, endodontic disorders and diseases, periodontal disorders and diseases, diabetes, ulcers, frostbite, dehydration, nutrition deficiency, respiratory disorders and diseases, pregnancy prevention, erectile dysfunction, hormone deficiency, hormone disorders and diseases, thyroid disorders and diseases, bone fractures, pulmonary hypertension, ocular and intraocular disorder and diseases, high cholesterol, osteoporosis, skin infections, fungal infections, skin infections, blood disorders and diseases, cancer, cardiovascular disorders and diseases, carpal tunnel syndrome, chronic pain, nerve disorders and diseases, degenerative nerve disorders and diseases, Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, spinal cord disorders and diseases, drug abuse, alcohol abuse, genitourinary and pelvic disorders and diseases, infertility, sexually transmitted diseases, incontinence, sexual dysfunction, urological diseases, glaucoma, headaches, hypocholesteremia, hyperlipidemia, immunologic disorders and diseases, autoimmune diseases, immunologic deficiency syndromes, infectious diseases, respiratory infections, eye infections, inflammatory connective tissue diseases and disorders, inflammatory diseases and disorders, inflammatory bowel disease, inflammatory muscle diseases and disorders, metabolic diseases and disorders, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity, hypothyroidism, migraines, motion sickness, myalgia, neuralgia, neurological diseases and disorders, cerebral palsy, brain injury, spinal cord injury, seizures, neuromuscular diseases and disorders, cerebrovascular accident, strokes, myasthenia gravis, oncological diseases and disorders, ophthalmological diseases and disorders, ophthalmological diseases and disorders, physical additions, psychological addictions, gambling addiction, eating disorders and addictions, nicotine addiction, Internet addiction, drug addiction, psychiatric diseases and disorders, brain diseases and disorders, anxiety, mood disorders, schizophrenia, cognitive disorders, bipolar disorders, respiratory diseases and disorders, skin irritations, bee stings, sunburn, rashes, sores, corns, calluses, central nervous system diseases and disorders, central nervous system infections, movement disorders, ocular motility disorders, spinal cord diseases, encephalitis, musculoskeletal system diseases and disorders, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, respiratory system diseases and disorders, varicose veins, vascular diseases, viral diseases, herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS), allergic rhinitis, asthma, dandruff, dermatology diseases and disorders, dermatitis, skin pigmentation diseases and disorders, smoking habits, gastroenterology diseases and disorders, wounds, dry skin, blood toxins, hematological diseases and disorders; disinfection systems, namely, all-purpose disinfectants | ACTIVE | — |
| 010 | Drug delivery systems, namely, needles, syringes, nasal spray bottles, injection devices, oral and nasal inhalation devices, patch pumps, and anesthetic delivery apparatus for medical purposes | ACTIVE | — |
| 035 | Consulting services relating to clinical trial services, namely, business and information management of clinical studies to fast track drug products to market | ACTIVE | — |
| 040 | Contract manufacturing of clinical batches of pharmaceuticals; Consulting services relating to pharmaceutical manufacturing and batch biological treatment batches; custom manufacture of pharmaceuticals, namely, the formulation of new dosage forms and the reformulation of existing drug products | ACTIVE | — |
| 042 | Consulting services relating to the clinical testing, inspection, or research of pharmaceuticals; Consulting services relating to conducting pharmaceutical stability studies and formal stability studies; Consulting services relating to the development of chemical production methods; Consulting services relating to registration batch research and commercial pharmaceutical products development | ACTIVE | — |
| 045 | Consulting services to assist companies with obtaining regulatory compliance and licenses for pharmaceuticals and medical devices; Consulting services relating to pharmaceuticals relating to regulatory compliance in the field of pharmaceuticals, namely, regulatory registration | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Septodont Holding SAS
- Other trademarks owned by Septodont Holding SAS
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 035
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 045
- Similar marks named NHI
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 1, 2019 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Apr 1, 2019 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Aug 28, 2018 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 3, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 3, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 13, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 30, 2018 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| May 25, 2018 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| May 24, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 3, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 3, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 3, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 3, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 23, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 23, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 23, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 23, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 23, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 23, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 19, 2018 | ALIE | ASSIGNED TO LIE | — |
| Apr 12, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 12, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 12, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 12, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 5, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 15, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 13, 2017 | NWAP | NEW APPLICATION ENTERED | — |